As global markets face pressure from rising US bond yields and a range of economic indicators, Hong Kong’s tech sector remains a hot topic for investors seeking high growth potential amid widespread market volatility. . In this environment, identifying strong stocks often requires looking for companies with robust innovation capabilities, strong financial health, and the ability to adapt to changing economic conditions.
name
increase in revenue
revenue growth
growth assessment
Medsai Healthcare Holdings
48.74%
48.78%
★★★★★☆
Inspur Digital Enterprise Technology
23.28%
38.76%
★★★★★☆
Innovent Biologics
21.96%
59.01%
★★★★★☆
remegen
26.23%
52.03%
★★★★★☆
Cowell E Holdings
31.68%
35.44%
★★★★★★
Akiso
33.50%
53.28%
★★★★★★
chinji game
54.54%
168.74%
★★★★★☆
Biocytogen Pharmaceuticals (Beijing)
21.53%
109.17%
★★★★★☆
beijing air dock technology
37.47%
93.35%
★★★★★☆
Sichuan Cologne-Biotech Biopharmaceutical
24.61%
7.62%
★★★★★☆
Click here to see the complete list of 43 stocks in the SEHK High Growth Technology Stock and AI Stock Screener.
Let’s consider some standout options from the screener results.
Simply Wall Street Growth Rating: ★★★★☆
Overview: AAC Technologies Holdings Inc. is an investment holding company that provides solutions for smart devices in various regions including Mainland China, Hong Kong, Taiwan, other Asian countries, the United States, and Europe, with a market capitalization of HK$36.91 billion. is.
What it does: AAC Technologies Holdings primarily generates revenue from its acoustic and electromagnetic drives and precision machinery segments, which contribute CA$7.64 billion and CA$8.28 billion, respectively. The company also generates revenue from optical products, sensors, and semiconductor products.
AAC Technologies Holdings has shown strong financial performance, with sales surging to 11.25 billion yuan in the first half of 2024, a significant increase from 9.22 billion yuan a year ago. This growth was supported by a significant increase in net profit from RMB 150 million to RMB 537 million, reflecting strong operational efficiency and market demand. The company’s commitment to innovation is evident in its R&D spending trends, which consistently match revenue growth and support future technological advances. AAC Technologies is aggressively expanding its business footprint and staying relevant in Hong Kong’s competitive technology environment, with recent strategic moves such as relocating its main office and participating in key industry conferences. I am.
story continues
SEHK: 2018 revenue and expense breakdown (as of October 2024)
Simply Wall Street Growth Rating: ★★★★☆
Overview: Kingsoft Corporation Limited operates in the fields of entertainment and office software and services in mainland China, Hong Kong and overseas, and has a market capitalization of approximately HK$36.42 billion.
Business Operations: Kingsoft Corporation Limited primarily derives its revenue from two segments. One is office software and services (CN 4.8 billion) and the other is entertainment software with CN 4.18 billion. The company operates in mainland China, Hong Kong, and overseas.
Kingsoft’s recent performance, with revenue for the first half of 2024 significantly increasing to 4.61 billion yuan from 4.16 billion yuan in the same period last year, highlights the company’s potential in Hong Kong’s technology sector. This growth was complemented by a significant increase in net profit to RMB 677.92 million due to effective strategy and market adaptation. The company’s investment in innovation is highlighted by R&D expenditures that closely match these financial indicators, ensuring sustained development and competitiveness in an evolving technology environment. Furthermore, Kingsoft has actively managed its capital through share buybacks totaling HK$592.96 million since the beginning of 2024, reflecting its confidence in its operational stability and future prospects.
SEHK:3888 Breakdown of revenue and expenses as of October 2024
Simply Wall Street Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical company engaged in the research, development, manufacturing and commercialization of antibody therapeutics with a market capitalization of HK$62.38 billion.
What it does: The Company is focused on the research, development, production and marketing of biopharmaceuticals and generates revenues of C$1.87 billion from these activities.
Akeso’s recent follow-on equity issue raised HK$1.94 billion, underscoring the company’s strategic financial strengthening amid significant clinical progress. The company’s strong commitment to research and development is evidenced by its robust revenue growth forecast of 33.5% driven by innovations such as cadnilimab for cervical cancer, indicating that the company is expected to increase its revenue by 53.3% annually. This is in line with the company’s aggressive development and commercialization strategy across oncology and non-oncology sectors, and despite extensive market challenges, Akeso remains a dynamic competitor in Hong Kong’s high-tech biopharmaceutical sector. It shows that there is.
SEHK:9926 Revenue and Revenue Growth as of October 2024
Start your investment journey here with SEHK’s selection of 43 high-growth technology and AI stocks.
Already own any of these companies? By linking your portfolio with Simply Wall St, you can clarify your investment decisions and easily monitor all the vital signs of a stock.
Join a community of smart investors with Simply Wall St. We provide expert-level analysis of markets around the world, for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodologies, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2018 SEHK:3888 and SEHK:9926.
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email us at editorial-team@simplywallst.com.
